{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:33:11Z","timestamp":1782858791543,"version":"3.54.5"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"am","delay-in-days":297,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA255044"],"award-info":[{"award-number":["R01 CA255044"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.steroids.2024.109482","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T17:06:07Z","timestamp":1721754367000},"page":"109482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer"],"prefix":"10.1016","volume":"210","author":[{"given":"Jon K.","family":"Obst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy H.","family":"Tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie C.","family":"Setiawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren F.","family":"Deneault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne D.","family":"Sadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.steroids.2024.109482_b0005","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-X","article-title":"The nuclear receptor superfamily: the second decade","volume":"83","author":"Mangelsdorf","year":"1995","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.steroids.2024.109482_b0010","first-page":"3","article-title":"Androgen receptor structure, function and biology: from bench to bedside","volume":"37","author":"Davey","year":"2016","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.steroids.2024.109482_b0015","first-page":"967","article-title":"Cardiovascular impact of androgen deprivation therapy: from basic biology to clinical practice","volume":"25","author":"Kim","year":"2023","journal-title":"Curr Oncl Rep."},{"key":"10.1016\/j.steroids.2024.109482_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: structure, role in prostate cancer and drug discovery","volume":"(36)1","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"13","key":"10.1016\/j.steroids.2024.109482_b0025","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1074\/jbc.270.13.7341","article-title":"Identification of two transcription activation units in the N-terminal domain of the human androgen receptor","volume":"270","author":"Jenster","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.steroids.2024.109482_b0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1097-2765(02)00471-9","article-title":"Formation of the androgen receptor transcription complex","volume":"9","author":"Shang","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.steroids.2024.109482_b0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20050872","article-title":"Structure and function of steroid receptor AF1 transactivation domains induction of active conformations","volume":"391","author":"Lavery","year":"2005","journal-title":"Biochem. J"},{"issue":"e001","key":"10.1016\/j.steroids.2024.109482_b0040","first-page":"1","article-title":"Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors","volume":"5","author":"McEwan","year":"2007","journal-title":"Nucl. Recept. Signal."},{"key":"10.1016\/j.steroids.2024.109482_b0045","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.csbj.2019.03.013","article-title":"Computational prediction of MoRFs, short disorder-to-order transitioning protein binding regions","volume":"17","author":"Katuwawala","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"7","key":"10.1016\/j.steroids.2024.109482_b0050","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/er.2007-0019","article-title":"Androgen Receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex","volume":"28","author":"Heemers","year":"2007","journal-title":"Endocr. Rev."},{"issue":"9","key":"10.1016\/j.steroids.2024.109482_b0055","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen signaling in prostate cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"9","key":"10.1016\/j.steroids.2024.109482_b0060","doi-asserted-by":"crossref","first-page":"7076","DOI":"10.1074\/jbc.M108255200","article-title":"Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways","volume":"277","author":"Ueda","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.steroids.2024.109482_b0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/edrv.23.2.0460","article-title":"Androgen receptor (AR) coregulators: an overview","volume":"23","author":"Heinlein","year":"2002","journal-title":"Endocr. Rev."},{"issue":"38","key":"10.1016\/j.steroids.2024.109482_b0070","doi-asserted-by":"crossref","first-page":"27882","DOI":"10.1074\/jbc.M605002200","article-title":"Ligand-independent androgen receptor activity is activation-function-2-independent and resistant to antiandrgogens in androgen refractory prostate cancer cells","volume":"281","author":"Dehm","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.steroids.2024.109482_b0075","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"NEJM"},{"issue":"1","key":"10.1016\/j.steroids.2024.109482_b0080","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1172\/JCI122819","article-title":"Androgen receptor splice variant-7 emerges with castration resistance in prostate cancer","volume":"129","author":"Sharp","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.steroids.2024.109482_b0085","first-page":"157","article-title":"Androgen receptor genomic regulation","volume":"2","author":"Jin","year":"2013","journal-title":"Transl Androl Urol."},{"issue":"7","key":"10.1016\/j.steroids.2024.109482_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gb-2002-3-7-research0032","article-title":"Transcriptional programs activated by exposure of human prostate cancer cells to androgen","volume":"3","author":"DePrimo","year":"2002","journal-title":"Genome Biol."},{"issue":"16","key":"10.1016\/j.steroids.2024.109482_b0095","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1101\/gad.1564207","article-title":"Cell- and gene-specific regulation of primary target genes of the androgen receptor","volume":"21","author":"Bolton","year":"2007","journal-title":"Genes Dev."},{"issue":"18","key":"10.1016\/j.steroids.2024.109482_b0100","doi-asserted-by":"crossref","first-page":"11890","DOI":"10.1073\/pnas.182376299","article-title":"The program of androgen-responsive genes in neoplastic prostate epithelium","volume":"99","author":"Nelson","year":"2002","journal-title":"PNAS"},{"issue":"2","key":"10.1016\/j.steroids.2024.109482_b0105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0012-1606(02)00031-3","article-title":"Hormonal cellular and molecular control of prostatic development","volume":"253","author":"Marker","year":"2003","journal-title":"Develop Biol."},{"issue":"12","key":"10.1016\/j.steroids.2024.109482_b0110","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.3390\/cells9122653","article-title":"Androgen receptor signaling pathway in prostate cancer from genetics to clinical applications","volume":"9","author":"Aurilio","year":"2020","journal-title":"Cells"},{"issue":"10013","key":"10.1016\/j.steroids.2024.109482_b0115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","article-title":"Prostate cancer","volume":"387","author":"Attard","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.steroids.2024.109482_b0120","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/0008-5472.CAN-06-3552","article-title":"The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression","volume":"67","author":"Verras","year":"2007","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.steroids.2024.109482_b0125","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1096\/fj.07-9360com","article-title":"Wild-type but not mutant androgen receptor inhibits expression of hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development","volume":"22","author":"Moehren","year":"2008","journal-title":"FASEB J."},{"issue":"16","key":"10.1016\/j.steroids.2024.109482_b0130","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1093\/nar\/gkq278","article-title":"Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells\u2013identification of a novel androgen response element","volume":"38","author":"Lanzino","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.steroids.2024.109482_b0135","first-page":"293","article-title":"Studies on prostatic Cancer: I the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.steroids.2024.109482_b0140","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2016","journal-title":"J. Am. Med. Assoc."},{"issue":"6","key":"10.1016\/j.steroids.2024.109482_b0145","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone sensitive prostate cancer: a systemic review and meta-analysis","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.steroids.2024.109482_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0090-4295(02)02393-2","article-title":"Hormonal therapy: historical perspective to future directions","volume":"61","author":"McLeod","year":"2003","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.steroids.2024.109482_b0155","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/13543784.10.4.709","article-title":"LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action","volume":"10","author":"Limonta","year":"2001","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"Suppl 3","key":"10.1016\/j.steroids.2024.109482_b0160","first-page":"S10","article-title":"Flare associated with LHRH-agonist therapy","volume":"3","author":"Thompson","year":"2001","journal-title":"Rev. Urol."},{"key":"10.1016\/j.steroids.2024.109482_b0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","article-title":"Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations","volume":"22","author":"Crawford","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"10.1016\/j.steroids.2024.109482_b0170","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat. Clin. Pract. Urol."},{"issue":"6","key":"10.1016\/j.steroids.2024.109482_b0175","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","article-title":"Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment","volume":"5","author":"Menges","year":"2022","journal-title":"Euro Urol Oncl."},{"issue":"8","key":"10.1016\/j.steroids.2024.109482_b0180","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1177\/1078155219835597","article-title":"Age dependent overall survival benefit of androgen deprivation therapy for metastatic prostate cancer","volume":"25","author":"Keating","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.steroids.2024.109482_b0185","first-page":"1","article-title":"Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management","volume":"2013","author":"Sountoulides","year":"2013","journal-title":"International Scholarly Research Notices."},{"issue":"5","key":"10.1016\/j.steroids.2024.109482_b0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bju.12964","article-title":"Adverse effects of androgen-deprivation therapy in prostate cancer and their management","volume":"115","author":"Rhee","year":"2015","journal-title":"BJU Int."},{"key":"10.1016\/j.steroids.2024.109482_b0195","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.steroids.2024.109482_b0200","first-page":"219","article-title":"Low levels of estradiol are associated with vertebral fractures in older men, but not women: the rancho bernado study","volume":"85","author":"Barrett-Connor","year":"2000","journal-title":"J. Clin. Endo. Metab."},{"issue":"20 Pt 2","key":"10.1016\/j.steroids.2024.109482_b0205","doi-asserted-by":"crossref","first-page":"6315s","DOI":"10.1158\/1078-0432.CCR-06-0846","article-title":"Treatment-related osteoporosis in men with prostate cancer","volume":"12","author":"Smith","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.steroids.2024.109482_b0210","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/ol802021w","article-title":"Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells","volume":"10","author":"Sadar","year":"2008","journal-title":"Org. Lett."},{"issue":"42","key":"10.1016\/j.steroids.2024.109482_b0215","doi-asserted-by":"crossref","first-page":"22231","DOI":"10.1074\/jbc.M116.734475","article-title":"Sintokamide A is a novel antagonist of androgen receptor that uniquely binds activation function-1 in its amino terminus domain","volume":"291","author":"Banuelos","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.steroids.2024.109482_b0220","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1158\/1535-7163.MCT-22-0237","article-title":"Discovery of a small-molecule inhibitor targeting the androgen receptor N-terminal domain for castration-resistant prostate cancer","volume":"22","author":"Yi","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.steroids.2024.109482_b0225","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41388-024-02944-2","article-title":"SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain","volume":"43","author":"Yi","year":"2024","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.steroids.2024.109482_b0230","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1172\/JCI66398","article-title":"An androgen receptor N-terminal domain antagonist for treating prostate cancer","volume":"123","author":"Myung","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.steroids.2024.109482_b0235","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1021\/acschembio.6b00182","article-title":"EPI-001, a compound active against castration-resistant prostate cancer, targets transactivation unit 5 of the androgen receptor","volume":"11","author":"De Mol","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"12_Supplement","key":"10.1016\/j.steroids.2024.109482_b0240","doi-asserted-by":"crossref","first-page":"P192","DOI":"10.1158\/1535-7163.TARG-21-P192","article-title":"Comprehensive preclinical characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor","volume":"20","author":"Hong","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.steroids.2024.109482_b0245","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/0008-5472.CAN-08-3605","article-title":"Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy","volume":"69","author":"Steinkamp","year":"2009","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.steroids.2024.109482_b0250","doi-asserted-by":"crossref","first-page":"e87850","DOI":"10.1172\/jci.insight.87850","volume":"1","author":"Imamura","year":"2016","journal-title":"JCI Insight."},{"key":"10.1016\/j.steroids.2024.109482_b0255","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cbpa.2014.10.021","article-title":"Covalent protein modification: the current landscape of residue-specific electrophiles","volume":"24","author":"Shannon","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.steroids.2024.109482_b0260","unstructured":"De Mol E.Structure, dynamics and interactions of the N-terminal domain of the androgen receptor. 2014 [Doctoral dissertation, University of Barcelona]."},{"issue":"1","key":"10.1016\/j.steroids.2024.109482_b0265","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.chembiol.2020.09.001","article-title":"Discovery of a functional covalent ligand targeting an intrinsically disordered cysteine within MYC","volume":"28","author":"Boike","year":"2021","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"10.1016\/j.steroids.2024.109482_b0270","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2211832120","article-title":"Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer","volume":"120","author":"Thiyagarajan","year":"2023","journal-title":"PNAS"},{"issue":"2","key":"10.1016\/j.steroids.2024.109482_b0275","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1021\/cb3005269","article-title":"Diverse functional roles of reactive cysteines","volume":"8","author":"Pace","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"10.1016\/j.steroids.2024.109482_b0280","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1110\/ps.04923305","article-title":"Intramolecular disulphide bond arrangements in nonhomologous proteins","volume":"14","author":"Hartig","year":"2005","journal-title":"Protein Sci."},{"issue":"28","key":"10.1016\/j.steroids.2024.109482_b0285","doi-asserted-by":"crossref","first-page":"9802","DOI":"10.1073\/pnas.0408819102","article-title":"The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions","volume":"102","author":"Schaufele","year":"2005","journal-title":"PNAS"},{"issue":"167","key":"10.1016\/j.steroids.2024.109482_b0290","first-page":"1","article-title":"Cysteines as redox molecular switches and targets of disease","volume":"10","author":"Fra","year":"2017","journal-title":"Front. Mol. Neurosci."},{"issue":"6","key":"10.1016\/j.steroids.2024.109482_b0295","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ccr.2010.04.027","article-title":"Regression of castrate-recurrent prostate cancer by a small molecule inhibitor of the amino-terminus domain of the androgen receptor","volume":"17","author":"Andersen","year":"2010","journal-title":"Cancer Cell."},{"issue":"11","key":"10.1016\/j.steroids.2024.109482_b0300","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-15-2119","article-title":"Cotargeting androgen receptor splice variants and mTOR signaling pathway for the treatment of castration-resistant prostate cancer","volume":"22","author":"Kato","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.steroids.2024.109482_b0305","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1878-0261.12770","article-title":"Combination therapy with ralaniten and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer","volume":"14","author":"Hirayama","year":"2020","journal-title":"Mol. Oncol."},{"issue":"11","key":"10.1016\/j.steroids.2024.109482_b0310","first-page":"2511","article-title":"Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist","volume":"59","author":"Taplin","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2024.109482_b0315","doi-asserted-by":"crossref","unstructured":"M. Korpal, J.M. Korn, X. Gao, D.P. Rakiec, D.A. Ruddy, S. Doshi, J. Yuan, S.G. Kovats, S. Kim, V.G. Cooke, J.E. Monahan, F. Stegmeier, T.M. Roberts, W.R. Sellers, W. Zhou, P. Zhu. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). 2013; 3(9):1030-1043. doi: 10.1158\/2159-8290.CD-13-0142.","DOI":"10.1158\/2159-8290.CD-13-0142"},{"issue":"17","key":"10.1016\/j.steroids.2024.109482_b0320","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1158\/1078-0432.CCR-15-2901","article-title":"Targeting Androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer","volume":"22","author":"Yang","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.steroids.2024.109482_b0325","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.steroids.2024.109482_b0330","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.steroids.2024.109482_b0335","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.steroids.2024.109482_b0340","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2024.109482_b0345","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-024-00829-9","article-title":"Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systemic review of prospective trials","author":"Shelan","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"1","key":"10.1016\/j.steroids.2024.109482_b0350","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bju.13026","article-title":"Non-steroidal antiandrogen monotherapy compared with luteinising hormone\u2013releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer","volume":"115","author":"Kunath","year":"2015","journal-title":"BJU Int."},{"issue":"158","key":"10.1016\/j.steroids.2024.109482_b0355","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)","volume":"13","author":"Maluf","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.steroids.2024.109482_b0360","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2265.1994.tb02585.x","article-title":"Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer","volume":"41","author":"Verhelst","year":"1994","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"10.1016\/j.steroids.2024.109482_b0365","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000019634","article-title":"A randomized comparison of \u2018casodex\u2019TM (Bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer","volume":"33","author":"Tyrrell","year":"1998","journal-title":"Eur. Urol."},{"issue":"13","key":"10.1016\/j.steroids.2024.109482_b0370","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.2004.01.174","article-title":"Bicalutamide monotherapy versus leurolide monotherapy for prostate cancer: effects on bone mineral density and body composition","volume":"22","author":"Smith","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.steroids.2024.109482_b0375","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide monotherapy in hormone-na\u00efve prostate cancer: primary analysis of an open-label, single-arm, phase 2 study","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.steroids.2024.109482_b0380","first-page":"V274","article-title":"EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N terminal domain (NTD) inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy. Genitourinary Tumours","volume":"28","author":"Vaishampayan","year":"2017","journal-title":"Prostate"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X2400120X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X2400120X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T06:28:54Z","timestamp":1728541734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X2400120X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":76,"alternative-id":["S0039128X2400120X"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2024.109482","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2024.109482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109482"}}